Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02962102 · ClinicalTrials.gov registry record · Phase 2
Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury
A Phase 2 study of Acute Kidney Injury and Critically Ill, sponsored by David Leaf.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT02962102: Completed Phase 2 study of Acute Kidney Injury and Critically Ill, sponsored by David Leaf.
NCT02962102 is a Phase 2 study of Acute Kidney Injury and Critically Ill that has completed, run by David Leaf. The registered enrollment target is 150 participants, below the 2,329-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02962102, a Phase 2 study of Acute Kidney Injury and Critically Ill, has completed, sponsored by David Leaf.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the efficacy of calcifediol (25-hydroxyvitamin D) and calcitriol (1,25-dihydroxyvitamin D) in preventing and reducing the severity of acute kidney injury (AKI) in critically ill patients.
Primary Outcome
All-cause mortality within 7 days following randomization
Conditions Studied
Interventions
- DRUG Placebos
- DRUG Calcitriol
- DRUG Calcifediol
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-04-03 |
| Est. Completion | 2020-08-06 |
| Phase | Phase 2 |
What the finished NCT02962102 record still lists
NCT02962102 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 2,329-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 3 interventions - of which Placebos is the first listed.
NCT02962102 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02962102 about?
NCT02962102 is a clinical study titled "Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury". The purpose of this study is to assess the efficacy of calcifediol (25-hydroxyvitamin D) and calcitriol (1,25-dihydroxyvitamin D) in preventing and reducing the severity of acute kidney injury (AKI) in critically ill patients.
What is the current status of trial NCT02962102?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2017-04-03. Estimated completion is 2020-08-06.
What conditions does trial NCT02962102 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Critically Ill.
What interventions are being tested in trial NCT02962102?
The interventions under investigation include: Placebos (DRUG), Calcitriol (DRUG), Calcifediol (DRUG).
Who is sponsoring clinical trial NCT02962102?
This trial is sponsored by David Leaf, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02962102 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02962102's enrollment target sits among peer trials
150 35th of 74 higher than 38 of 74 other Acute Kidney Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
RECRUITING · Phase 2
-
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI